Introduction: Pneumocystis pneumonia (PCP) is a common and serious complication of HIV/AIDS, with a higher prevalence in patients not receiving antiretroviral therapy. Due to the high mortality rate of PCP, accurate prediction of its case fatality rate is very important for clinical treatment. We aimed to develop a risk model for the near-term prognosis of people with HIV/AIDS and PCP and verify its effectiveness.

Methods: This single-center, retrospective observational study was conducted at Beijing Youan Hospital from January 2012 to October 2022. 972 AIDS patients with Pneumocystis pneumonia met our criteria were recruited. The patients were divided into death group and survival group according to clinical outcome during hospitalization. Data of the two groups were collected including general information and laboratory test results. 53 medical characteristics of the two groups were collected. Prediction variables were screened with Multivariate logistic regression analysis and Lasso regression model. We used ROC curve to identify the discrimination of training and testing data sets. The Shapley Additive exPlanation (SHAP) method was applied to explain the final model and the weights of features.

Results: The overall mortality rate among hospitalized patients was 17.8%. We found that the best prediction effect can be obtained when ALB, PO, TBIL, LDH, CD4 T lymphocyte counts are incorporated into the PCP risk prediction model. The model had a perfect discrimination with AUC of 0.994 and 0.947 in training and validation cohorts. The prognosis risk grade was divided into three grades: low-risk group (0-25 points with mortality of 5.9%), moderate-risk group (25-50 points with mortality of 45.1%) and high-risk group (above 50 points with mortality of 80%). There is a statistically significant difference in mortality among these three grades (χ = 419.271, P<0.001).

Conclusion: We developed and validated a model of the prognostic risk level of PCP in patients of AIDS with the results of blood tests reviewed by patients at routine visits. The model is more convenient to use, allowing clinicians to obtain a determined probability value of PCP mortality with simple calculations within the first 72 hours of the patient's admission.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11842385PMC
http://dx.doi.org/10.3389/fcimb.2024.1485231DOI Listing

Publication Analysis

Top Keywords

pneumocystis pneumonia
12
points mortality
12
risk prediction
8
prediction model
8
aids patients
8
patients pneumocystis
8
mortality rate
8
groups collected
8
three grades
8
mortality
7

Similar Publications

The status of coinfection during the national outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.5.2 or BF.

View Article and Find Full Text PDF

Objective: Predicting the occurrence of hyperkalemia in patients undergoing co-trimoxazole treatment for Pneumocystis pneumonia is critical. However, other factors besides drug exposure affect serum potassium levels, and various interventions are often used to treat hyperkalemia in clinical practice. Therefore, we aimed to develop a Markov model to predict the risk of hyperkalemia under various intervention conditions.

View Article and Find Full Text PDF

Comparison of CURB-65 and qSOFA Combined with Serum Markers and HRCT in Predicting Mortality in AIDS with Pneumocystis jirovecii Pneumonia.

J Coll Physicians Surg Pak

March 2025

Department of Respiratory and Critical Care Medicine, Beijing Youan Hospital, Capital Medical University, Beijing, China.

Objective: To evaluate and compare the clinical predictive value of the CURB-65 and qSOFA scores, combined with serum markers and HRCT scores, in assessing mortality risk in Acquired Immunodeficiency Syndrome (AIDS) patients with Pneumocystis jirovecii pneumonia (PJP).

Study Design: Descriptive analytical study. Place and Duration of the Study: Department of Respiratory and Critical Care Medicine, Beijing Youan Hospital, Capital Medical University, Beijing, China, from January to December 2022.

View Article and Find Full Text PDF

Bronchoalveolar lavage fluid (BALF) is the key sample type for diagnosing Pneumocystis jirovecii pneumonia, with quantitative PCR (qPCR) providing high sensitivity and specificity. However, sample processing varies considerably between laboratories, and optimal nucleic acid extraction method for BALF remains undetermined. This retrospective multicenter study, conducted in 12 centers as part of the Fungal PCR Initiative, assessed the efficacy of P.

View Article and Find Full Text PDF

Critically ill COVID-19 patients are at high risk for invasive fungal infections (IFIs). Data on IFI prevalence in severe COVID-19 patients in Latin America is scarce. This study aimed at analyzing the prevalence and outcomes of IFIs in COVID-19 patients from Argentina.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!